new york times glp 1 Hims & Hers promotes GLP-1 obesity drugs in The Disruptive Power of Weight
Description
Proportion of caloric restriction-induced weight loss as skeletal muscle
Jones B, Buenaventura T, Kanda N, et al
Bright Focus Foundation
Patients were followed from 1 year after cohort entry until a diagnosis of incident adverse CVEs, switch to a comparator drug, any cause of death or the end of the study (30 September 2022), whichever occurred first
thus, its loss may exacerbate metabolic adaptation and increase vulnerability to rebound weight gain following treatment discontinuation
